<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01221831</url>
  </required_header>
  <id_info>
    <org_study_id>ES-C02</org_study_id>
    <secondary_id>2010-019865-26</secondary_id>
    <nct_id>NCT01221831</nct_id>
  </id_info>
  <brief_title>Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2</brief_title>
  <acronym>FIESTA</acronym>
  <official_title>A Randomised Open-label Multi-centre Comparative Study to Evaluate Cycle Control of 2 Dosages of Estetrol Combined With Either P1 or P2, Compared to a Combined Oral Contraceptive Containing E2V and DNG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Estetra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Estetra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-centre, comparative study in young, healthy, female volunteers
      of reproductive age.

      Primary objective:

      - To investigate the effect of 2 dosages of estetrol combined with P1 or P2, on vaginal
      bleeding patterns (cycle control), in comparison with a combined oral contraceptive
      containing estradiol valerate and dienogest

      Secondary objectives:

        -  To investigate ovulation inhibition

        -  To investigate the effect on SHBG

        -  To assess pregnancy rate

        -  To evaluate subject satisfaction, dysmenorrhoea, acne, and body weight

        -  To investigate return of menstruation after treatment

        -  To evaluate general safety and acceptability
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recording of vaginal bleeding events (diary) as a measure of Cycle control</measure>
    <time_frame>6 cycles of 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of pregnandiol glucuronide in urine as a measure of Ovulation inhibition</measure>
    <time_frame>6 cycles of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome questionnaire as a measure of Subject satisfaction</measure>
    <time_frame>6 cycles of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contacts patient-investigator to document Return of menstruation</measure>
    <time_frame>for up to 1 year follow-up</time_frame>
    <description>(only in case the patient does not start up a new hormonal contraceptive method or in case of pregnancy wish)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording of adverse events, physical examination and laboratory parameters as a measure of Safety and Tolerability</measure>
    <time_frame>up to 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of SHBG in blood samples to assess the effect of treatment on SHBG</measure>
    <time_frame>6 cycles of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reporting of in-treatment pregnancies as a measure of pregnancy rate</measure>
    <time_frame>6 cycles of 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">396</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>estetrol dose 1 / P1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>estetrol dose 1 / P2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>estradiol valerate/dienogest pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>estetrol dose 2 / P1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>estetrol dose 2 / P2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estetrol, P 1 and placebo tablets</intervention_name>
    <description>6 treatment cycles each consisting of 28 days of oral administration as follows:
Days 1-24: one estetrol tablet and one P1 tablet per day
Days 25-28: two placebo tablets per day</description>
    <arm_group_label>estetrol dose 1 / P1</arm_group_label>
    <arm_group_label>estetrol dose 2 / P1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estetrol, P2 and placebo tablets</intervention_name>
    <description>6 treatment cycles each consisting of 28 days of oral administration as follows:
Days 1-24: one estetrol tablet and one P2 tablet per day
Days 25-28: two placebo tablets per day</description>
    <arm_group_label>estetrol dose 1 / P2</arm_group_label>
    <arm_group_label>estetrol dose 2 / P2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol valerate, dienogest and placebo tablets</intervention_name>
    <description>6 treatment cycles each consisting of 28 days of oral administration as follows:
Days 1-26: one tablet of Estradiol valerate/dienogest per day
Days 26-28: one placebo tablet per day</description>
    <arm_group_label>estradiol valerate/dienogest pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women willing to use a Combined Oral Contraceptive for 6 subsequent cycles

          -  Good physical and mental health

          -  Regular menstrual cycle (24-35 days) prior to screening

          -  Body mass index between (≥) 18 and (≤) 30 kg/m2

        Exclusion Criteria:

          -  Previous use of any hormonal contraceptive method during the last 3 months prior to
             randomisation (only applicable for women who are not using a hormonal contraceptive
             method at the time of screening)

          -  Previous use of progestogen-only contraceptive methods during the last 3 months or
             during the last 6 months for depot progestogen preparations or an injectable hormonal
             method of contraception

          -  Use of phytoestrogens

          -  No spontaneous menstruation has occurred following a delivery or abortion

          -  Breastfeeding or within 2 months after stopping breastfeeding prior to the start of
             study medication and no spontaneous return of menstruation

          -  Status post-partum or post-abortion within a period of 2 months before screening

          -  Pregnancy during accurate hormonal contraceptive use in the past

          -  Intention to become pregnant during the study

          -  An abnormal cervical smear within one year before study start

          -  Untreated Chlamydia infection

          -  Known or suspected breast cancer or a history of breast cancer

          -  A history of (within 12 months) alcohol or drug abuse

          -  Any clinically relevant abnormality

          -  Contraindications for the contraceptive steroids used in the clinical trial

          -  Use of antihypertensive drugs or use of medications interacting with the contraceptive
             steroids used in the clinical trial

          -  Administration of any other investigational drug within 2 months prior to screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Apter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Väestöliitto Helsinki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mehiläinen Helsinki</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Väestöliitto Helsinki</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YTHS Jyvaskyla</name>
      <address>
        <city>Jyvaskyla</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratorio Simpanen</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terveystalo Kuopio</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YTHS Kuopio</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Väestöliitto Oulu</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen Lääkärikeskus Oy</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YTHS Tampere</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Väestöliitto Turku</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2010</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

